Is Cetrorelix FDA approved?

Cetrorelix is FDA approved (FDA status current as of 1999-06-03). This regulatory status is provided for research and educational context only.

Is Triptorelin FDA approved?

Triptorelin is FDA approved (FDA status current as of 2000-06-15). This regulatory status is provided for research and educational context only.

How is Cetrorelix administered in research settings?

In research settings, Cetrorelix is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is Triptorelin administered in research settings?

In research settings, Triptorelin is typically administered via the subcutaneous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cetrorelix vs Triptorelin

Peptide Comparison

Cetrorelix vs Triptorelin

Q: What is the difference between Cetrorelix and Triptorelin?

Cetrorelix: Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression Triptorelin: Potent GnRH agonist; single pulse stimulates LH/FSH surge and restores HPG axis after suppression (e.g., post-steroid cycle)

Both are Reproductive & Hormonal peptides.

Cetrorelix

Cetrotide

Sexual HealthFDA ApprovedPrescription

Half-life: ~62 hours

1 providers listed

Full Cetrorelix profile →

Triptorelin

Decapeptyl

Sexual HealthFDA ApprovedPrescription

Half-life: ~7-8 hours (single dose) / ~5-7 weeks (depot form)

1 providers listed

Full Triptorelin profile →

Bottom line

Triptorelin has a longer half-life than Cetrorelix, so it generally needs less frequent dosing.

Quick Verdict

Cetrorelix

Evidence

Established Clinical

Half-life

~62 hours

Triptorelin

Evidence

Established Clinical

Half-life

~7-8 hours (single dose) / ~5-7 weeks (depot form)

Which One Should You Choose?

Your goal	Better option
Less frequent dosing (longer half-life)	Triptorelin

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cetrorelix

Triptorelin

Mechanism Family

Reproductive & Hormonal

Half-life

~62 hours

~7-8 hours (single dose) / ~5-7 weeks (depot form)

FDA Status

approved

Admin Routes

subcutaneous

subcutaneous, intramuscular

Availability

Prescription

Providers

1 listed

FDA Update

Jun 1999

Jun 2000

Avail. Notes

FDA-approved GnRH antagonist. Brand: Cetrotide (NDA 021036, Jun 1999). Prevents premature LH surges in controlled ovarian stimulation. Prescription only.

FDA-approved GnRH agonist. Brand: Trelstar (NDA 020726, Jun 2000). Indicated for advanced prostate cancer. Also used off-label for precocious puberty and chemical castration. Prescription only.

Research Evidence

Cetrorelix

Established ClinicalMeta-analysis · 7 key studies · most recent 2026

Triptorelin

Established ClinicalMeta-analysis · 8 key studies · most recent 2026

Research Citations

Cetrorelix

Meta-analysis2026 · J Coll Physicians Surg Pak

GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis.

Meta-analysis2023 · Hum Reprod Update

Optimal GnRH antagonist protocol for ovarian stimulation during ART: systematic review and network meta-analy…

Cohort2026 · Eur J Pharm Sci

Hydrogel and oleogel formulation of the decapeptide cetrorelix acetate for nasal administration.

Cohort2026 · Int J Reprod Biomed

Efficacy and safety of different cetrorelix doses in the luteal phase for preventing ovarian hyperstimulation…

+3 more

Triptorelin

Meta-analysis2026 · J Coll Physicians Surg Pak

GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis.

RCT2016 · Journal of Pediatric Endocrinology and Metabolism

Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty

Cohort2026 · J Med Case Rep

In vitro fertilization-frozen embryo transfer in a patient with gonadotroph adenoma: Exacerbation of ovarian…

Cohort2026 · Zhongguo Dang Dai Er Ke Za Zhi

[Efficacy of the 3-month formulation of triptoreli in children with idiopathic central precocious puberty].

+4 more

About Cetrorelix

Competitive GnRH receptor antagonist; immediately blocks pituitary GnRH receptors; rapidly suppresses LH/FSH without initial flare effect; used for controlled hormonal suppression

Research Areas

HPG axis suppressionLH/FSH reductioncontrolled ovarian stimulation supporttestosterone management

About Triptorelin

Potent GnRH agonist; single pulse stimulates LH/FSH surge and restores HPG axis after suppression (e.g., post-steroid cycle)

Research Areas

HPG axis restarttestosterone restorationHPTA recovery

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cetrorelix

Absolute Contraindications

Pregnancy — contraindicatedLactation — contraindicated

Source: FDA label

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Triptorelin

Reported (Unverified — Pending Clinical Review)

ongoing TRTactive hormonal therapy

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Find Providers

Where to source these peptides

Providers offering

Cetrorelix

1 listed

Browse directory →

Providers offering

Triptorelin

1 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Reproductive & Hormonal Comparisons

Browse all peptides →

Educational research tools — not medical advice.